Ishares Genomics Immunology Etf Price To Earning
| IDNA Etf | USD 24.10 0.07 0.29% |
iShares Genomics Immunology fundamentals help investors to digest information that contributes to IShares Genomics' financial success or failures. It also enables traders to predict the movement of IShares Etf. The fundamental analysis module provides a way to measure IShares Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IShares Genomics etf.
IShares |
iShares Genomics Immunology ETF Price To Earning Analysis
IShares Genomics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
IShares Genomics Price To Earning Component Assessment
Based on the latest financial disclosure, iShares Genomics Immunology has a Price To Earning of 0.0 times. This is 100.0% lower than that of the iShares family and 100.0% lower than that of the Health category. The price to earning for all United States etfs is 100.0% higher than that of the company.
Did you try this?
Run Financial Widgets Now
Financial WidgetsEasily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
| All Next | Launch Module |
Fund Asset Allocation for IShares Genomics
The fund invests 99.56% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides IShares Genomics' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
IShares Fundamentals
| Number Of Employees | 403 | |||
| Beta | 1.15 | |||
| Total Asset | 170.27 M | |||
| One Year Return | 17.00 % | |||
| Three Year Return | (17.90) % | |||
| Five Year Return | (3.00) % | |||
| Net Asset | 170.27 M | |||
| Last Dividend Paid | 0.24 | |||
| Equity Positions Weight | 99.56 % |
About IShares Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iShares Genomics Immunology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IShares Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iShares Genomics Immunology based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Genomics Imm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Genomics Immunology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Genomics Immunology Etf:Check out IShares Genomics Piotroski F Score and IShares Genomics Altman Z Score analysis. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.